SCHEMBL13939151

SCHEMBL13939151

COCCOc1cc(/N=C2/NC(=O)/C(=C/c3ccc4ncccc4c3)S2)c(Cl)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 5/20 0.67
CDK1 P06493 4/20 0.52
PRKCD Q05655 3/20 0.52
GSK3B P49841 3/20 0.52
CCNB1 P14635 2/20 0.52
MAPK1 P28482 2/20 0.52
AURKA O14965 1/20 0.52
CCNT1 O60563 1/20 0.52
CCNA2 P20248 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
GSK3A P49840 1/20 0.52
CDK7 P50613 1/20 0.52
CDK9 P50750 1/20 0.52
CCNH P51946 1/20 0.52
MNAT1 P51948 1/20 0.52
CDK5 Q00535 1/20 0.52
CDK5R1 Q15078 1/20 0.52
AURKB Q96GD4 1/20 0.52
CLK1 P49759 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2789892 1.00 DYRK3 (0.67) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL2789895 1.00 DYRK3 (0.67) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL2788194 0.87 DYRK3 (0.67) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL13197020 0.87 DYRK3 (0.67) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL2788188 0.87 DYRK3 (0.67) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL4770650 0.86 DYRK3 (0.48) DYRK3GSK3BCLK1CLK3DYRK1A
SCHEMBL13196821 0.81 DYRK3 (1.00) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL2786117 0.81 DYRK3 (1.00) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL2786118 0.81 DYRK3 (1.00) DYRK3CDK1PRKCDGSK3BCCNB1
SCHEMBL2786592 0.81 DYRK3 (0.73) DYRK3CDK1PRKCDGSK3BCCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023742-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed
US-20090023742-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023742-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA DYRK3 1357/4885CDK1 723/4885PRKCD 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.